Accession Number: | 0001209191-22-046291 |
Date: | 2022-08-17 |
Issuer: | TURNING POINT THERAPEUTICS, INC. (TPTX) |
Original Submission Date: |
NICHOLSON GARRY A
C/O TURNING POINT THERAPEUTICS, INC.
10628 SCIENCE CENTER DRIVE, STE. 200
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 59.11 | 2022-08-17 | deemed execution date | D | 23,400 (d) | 2030-01-21 | common stock 23,400 | $59.11 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 65.64 | 2022-08-17 | deemed execution date | D | 8,500 (d) | 2031-06-01 | common stock 8,500 | $65.64 | 0 | direct |
ID | footnote |
---|---|
f1 | pursuant to the agreement and plan of merger (the "merger agreement"), dated as of june 2, 2022, by and among turning point therapeutics, inc. (the "issuer"), bristol-myers squibb company ("bms") and rhumba merger sub inc., a wholly owned subsidiary of bms ("purchaser"), on august 17, 2022, purchaser completed a tender offer for shares of common stock of the issuer (each, a "share") and thereafter merged with and into the issuer, with the issuer continuing as the surviving corporation and a wholly owned subsidiary of bms (the "merger"). |
f2 | at the effective time of the merger, pursuant to the merger agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of shares subject to such option multiplied by (ii) the excess of (x) $76.00 per share over (y) the exercise price payable per share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |